Drug Trial Radar · NCT07281937
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
206
Actual
Start
Nov 25, 2025
Primary completion
Jul 23, 2026
Study completion Jul 23, 2026
Sponsor
- Lead sponsor
- Verdiva Bio Dev LimitedIndustry
- Sponsor type
- Industry
- First posted
- Dec 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.
Conditions
- Obesity
- Overweight
Interventions
VRB-101Drug
VRB-101 tablets will be administered orally.
PlaceboDrug
Placebo tablets will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean percent change from baseline in body weightTime frame: From Baseline (Day 0) up to Week 21
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Clinical Study Site 103
Anniston, Alabama
Clinical Study Site 109
Cullman, Alabama
Clinical Study Site 110
Phoenix, Arizona
Clinical Study Site 113
Little Rock, Arkansas
Clinical Study Site 111
Anaheim, California
Clinical Study Site 107
Montclair, California
Clinical Study Site 118
Tarzana, California
Clinical Study Site 119
Decatur, Georgia
Clinical Study Site 116
West Des Moines, Iowa
Clinical Study Site 106
Wichita, Kansas
Clinical Study Site 122
Southfield, Michigan
Clinical Study Site 121
Omaha, Nebraska
Clinical Study Site 117
Binghamton, New York
Clinical Study Site 101
Rochester, New York
Clinical Study Site 120
Charlotte, North Carolina
Clinical Study Site 108
Monroe, North Carolina
Clinical Study Site 105
Norman, Oklahoma
Clinical Study Site 114
Duncansville, Pennsylvania
Clinical Study Site 115
Knoxville, Tennessee
Clinical Study Site 112
Dallas, Texas
Clinical Study Site 102
San Antonio, Texas
Clinical Study Site 104
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.